Bioretec Oy

BRETEC.HE has a market price of 0.0226 EUR and a market capitalization of 30,324,362.76 EUR, with a price-to-book ratio of 3.11 and a price-to-tangible-book ratio of 3.11. The company's liquidity position is characterized by a current ratio of 5.18 and a cash and equivalents balance of 4,125,530 EUR, indicating a strong short-term liquidity position. However, the company's operating cash flow is negative at -9,762,260 EUR, and its free cash flow is also negative at -9,856,470 EUR, suggesting challenges in generating positive cash flow from operations.

The company's profitability is weak, with a return on equity of -0.9714 and a return on assets of -0.812, both significantly below the industry median for medical equipment and supplies. The operating income is negative at -8,685,810 EUR, and the net income is also negative at -9,482,730 EUR, indicating a substantial loss for the period. The gross profit of 2,314,280 EUR is relatively low compared to the company's revenue of 3,521,650 EUR, suggesting a low margin business model.

BRETEC.HE's revenue is concentrated in the healthcare services and equipment industry, with no disclosed geographic diversification in the provided data. The company's capital expenditure of -583,740 EUR indicates a reduction in capital spending, which may reflect a strategic shift or financial constraints. The company's debt-to-equity ratio is 0.04, indicating a low level of leverage and a conservative capital structure.

The company's growth trajectory is uncertain, with no specific revenue growth or decline figures provided in the outlook. The negative operating and net income figures suggest a challenging operating environment, and the company may need to address its profitability to sustain long-term growth. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the company's negative cash flows and operating losses may pose long-term sustainability risks.

Recent events and filings do not indicate any significant changes in the company's operations or financial position. The analyst estimates suggest a neutral outlook, with a mean price target of 0.02 EUR and a mean recommendation of 4.00, indicating a hold rating. The lack of strong buy or buy recommendations suggests limited investor confidence in the company's near-term prospects.